A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present

Muhammad Begawan Bestari,Ignatius Ronaldi Joewono,Ari Fahrial Syam

DOI: https://doi.org/10.3390/biom14030364

IF: 6.064

2024-03-19

Biomolecules

Abstract:Pancreatic cancer (PC) is the most lethal type of cancer; it has the lowest 5-year survival rate among all other types of cancers. More than half of PC cases are diagnosed at an advanced stage due to PC's insidious and non-specific symptoms. Surgery remains the most efficacious treatment option currently available, but only 10–20% of PC cases are resectable upon diagnosis. As of now, the sole biomarker approved by the United States Food and Drug Administration (US-FDA) for PC is carbohydrate antigen 19-9 (CA19-9); however, its use is limited for early diagnosis. An increasing number of studies have investigated a combination of biomarkers. Lately, there has been considerable interest in the application of a liquid biopsy, including the utilization of microRNAs (miRNAs), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs). Screening for PC is indicated for high-risk patients; studies on new diagnostic models combined with biomarkers for early detection have also shown promising results in terms of the ability of these models and biomarkers to aid clinicians in deciding on whether to start screening. This review seeks to provide a concise overview of the advancements in relation to existing biomarkers and explore novel strategies for the early detection of PC.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the difficult problem of early diagnosis of pancreatic cancer (PC). Specifically:

1. **Early Diagnosis Challenges**: Pancreatic cancer is one of the most deadly types of cancer, with the lowest 5 - year survival rate among all cancers. More than half of pancreatic cancer cases are diagnosed at an advanced stage, mainly because the early symptoms are insidious and non - specific. Therefore, early diagnosis is crucial for improving the survival rate of patients.

2. **Limitations of Existing Biomarkers**: Currently, the only biomarker approved by the United States Food and Drug Administration (US - FDA) for pancreatic cancer is carbohydrate antigen 19 - 9 (CA19 - 9), but its application in early diagnosis is limited. CA19 - 9 can also be elevated in other types of tumors, and about 10% of the population cannot synthesize this antigen due to blood type reasons.

3. **Exploration of New Biomarkers**: In order to overcome the limitations of existing biomarkers, researchers are exploring new biomarkers, such as protein markers (e.g., LGR1, MMPs, TIMPs, TTR, ICAM - 1, OPG), microRNAs (miRNAs), circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). The potential and feasibility of these new markers in early diagnosis are the focus of this paper.

4. **Application of Combined Markers**: The use of a single biomarker may lead to a relatively high false - positive rate and false - negative rate. Therefore, the study also explores the use of combinations of multiple biomarkers to improve the sensitivity and specificity of early diagnosis.

In summary, this paper aims to explore more effective early diagnosis methods for pancreatic cancer by reviewing existing early biomarkers and their latest progress, thereby improving the survival rate and treatment effect of patients.